Denali Therapeutics Inc. (DNLI) company profile

Denali Therapeutics discovers and develops biotherapeutic medicines designed to treat serious conditions, primarily central nervous system diseases, lysosomal storage disorders, and neurodegenerative illnesses like Alzheimer's and Parkinson's. The company utilizes its proprietary TransportVehicle platform, an engineering approach that leverages receptor-mediated pathways to transport large molecules such as enzymes, oligonucleotides, and antibodies across the blood-brain barrier. Its pipeline includes enzyme replacement therapies such as tividenofusp alfa for Hunter syndrome and DNL126 for Sanfilippo syndrome type A, alongside programs targeting tau and amyloid pathologies in Alzheimer's disease and small-molecule candidates for Parkinson's disease. Denali serves patients with severe genetic and neurodegenerative conditions, collaborating with biopharmaceutical partners like Biogen and Takeda for clinical development and commercialization.

The company operates a clinical biomanufacturing facility located in Salt Lake City, Utah, to expand its domestic manufacturing capacity. Denali shares development and commercialization rights in the United States and China for key partnered programs. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Denali Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025 , we had approximately 503 full-time employees.”